332 related articles for article (PubMed ID: 22883370)
1. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].
Gendrel D
Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370
[TBL] [Abstract][Full Text] [Related]
2. Challenges for development of meningococcal vaccines in infants and children.
Deasy A; Read RC
Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
[TBL] [Abstract][Full Text] [Related]
3. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
4. Optimizing protection against meningococcal disease.
Reisinger KS; Black S; Stoddard JJ
Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.
Sáfadi MA; McIntosh ED
Expert Rev Vaccines; 2011 Dec; 10(12):1717-30. PubMed ID: 22085175
[TBL] [Abstract][Full Text] [Related]
7. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
Papaevangelou V; Spyridis N
Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
[TBL] [Abstract][Full Text] [Related]
8. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal vaccine evolution.
Bona G; Guidi C
J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
[TBL] [Abstract][Full Text] [Related]
11. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
Pace D
Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
[TBL] [Abstract][Full Text] [Related]
12. [Meningococcal vaccine. Editorial].
Gendrel D; Cohen R
Arch Pediatr; 2012 Sep; 19 Suppl 2():S47-8. PubMed ID: 22883365
[No Abstract] [Full Text] [Related]
13. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
Yogev R; Tan T
Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
[TBL] [Abstract][Full Text] [Related]
14. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
15. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.
Bröker M; Veitch K
Travel Med Infect Dis; 2010 Jan; 8(1):47-50. PubMed ID: 20188306
[TBL] [Abstract][Full Text] [Related]
16. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
17. Evolving meningococcal immunization strategies.
Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
[TBL] [Abstract][Full Text] [Related]
18. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.
Poland GA
Clin Infect Dis; 2010 Mar; 50 Suppl 2():S45-53. PubMed ID: 20144016
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.
Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG
PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699
[TBL] [Abstract][Full Text] [Related]
20. [Paediatric meningococcal meningitis in France: ACTIV/GPIP network results].
Levy C; Taha MK; Bingen E; Cohen R;
Arch Pediatr; 2012 Sep; 19 Suppl 2():S49-54. PubMed ID: 22883366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
